In silico models for drug-induced liver injury – current status

Introduction: Drug-induced liver injury (DILI) is one of the most important reasons for drug attrition at both pre-approval and post-approval stages. Therefore, it is crucial to develop methods that will detect potential hepatotoxicity among drug candidates as early and quickly as possible. However, the complexity of hepatotoxicity endpoint makes it very difficult to predict. In addition, there is still a lack of sensitive and specific biomarkers for DILI that consequently leads to a scarcity of reliable hepatotoxic data, which are the key to any modelling approach. Areas covered: This review explores the current status of existing in silico models predicting hepatotoxicity. Over the past decade, attempts have been made to compile hepatotoxicity data and develop in silico models, which can be used as a first-line screening of drug candidates for further testing. Expert opinion: Most of the predictive methods discussed in this review are based on the structural properties of chemicals and do not take into account genetic and environmental factors; therefore, their predictions are still uncertain. To improve the predictability of in silico models for DILI, it is essential to better understand its mechanisms as well as to develop sensitive toxicogenomics biomarkers, which show relatively good differentiation between hepatotoxins and non-hepatotoxins.

[1]  R. Stierum,et al.  The introduction of toxicogenomics; potential new markers of hepatotoxicity. , 2005, Cancer biomarkers : section A of Disease markers.

[2]  G. Betton,et al.  The predictivity of the toxicity of pharmaceuticals in humans from animal data--an interim assessment. , 1998, Toxicology letters.

[3]  M T D Cronin,et al.  A review of the electrophilic reaction chemistry involved in covalent protein binding relevant to toxicity , 2011, Critical reviews in toxicology.

[4]  Alexander Tropsha,et al.  Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. , 2010, Chemical research in toxicology.

[5]  Douglas M. Hawkins.  Topics in Applied Multivariate Analysis , 1982 .

[6]  D. Thompson,et al.  Role of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity , 2005, Critical reviews in toxicology.

[7]  D. Pessayre,et al.  Hepatotoxicity due to mitochondrial dysfunction , 2004, Cell Biology and Toxicology.

[8]  J. Ozer,et al.  The current state of serum biomarkers of hepatotoxicity. , 2008, Toxicology.

[9]  M. Black,et al.  Drug induced liver disease. , 1983, Postgraduate medical journal.

[10]  Petra S Kern,et al.  TIMES-SS--a promising tool for the assessment of skin sensitization hazard. A characterization with respect to the OECD validation principles for (Q)SARs and an external evaluation for predictivity. , 2007, Regulatory toxicology and pharmacology : RTP.

[11]  R. E. Wilson,et al.  Blood gene expression signatures predict exposure levels , 2007, Proceedings of the National Academy of Sciences.

[12]  I. Grattagliano,et al.  Effect of acetaminophen administration on hepatic glutathione compartmentation and mitochondrial energy metabolism in the rat. , 1996, Biochemical pharmacology.

[13]  W. Suter.  Predictive value of in vitro safety studies. , 2006, Current opinion in chemical biology.

[14]  J. Senior,et al.  How can ‘Hy's law’ help the clinician? , 2006, Pharmacoepidemiology and drug safety.

[15]  Steven L. Dixon,et al.  Investigation of classification methods for the prediction of activity in diverse chemical libraries , 1999, J. Comput. Aided Mol. Des..

[16]  Philippa R. N. Wolohan,et al.  Modelling in vitro hepatotoxicity using molecular interaction fields and SIMCA. , 2004, Journal of molecular graphics & modelling.

[17]  N. Kaplowitz,et al.  c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. , 2006, Gastroenterology.

[18]  T. Baillie,et al.  Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. , 2001, Chemical research in toxicology.

[19]  J. Waring,et al.  Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development. , 2009, Toxicology letters.

[20]  J. Lindon,et al.  Pharmaco-metabonomic phenotyping and personalized drug treatment , 2006, Nature.

[21]  M. Fielden,et al.  The liver pharmacological and xenobiotic gene response repertoire , 2008, Molecular systems biology.

[22]  Dominic P. Williams,et al.  Toxicophores: investigations in drug safety. , 2006, Toxicology.

[23]  M. T. D. Cronin.  Chapter 3:Finding the Data to Develop and Evaluate (Q)SARs and Populate Categories for Toxicity Prediction , 2010 .

[24]  M. Natália D. S. Cordeiro,et al.  Computational chemistry approach for the early detection of drug‐induced idiosyncratic liver toxicity , 2008, J. Comput. Chem..

[25]  Shufeng Zhou,et al.  Bioactivation and hepatotoxicity of nitroaromatic drugs. , 2006, Current drug metabolism.

[26]  C. Degott,et al.  Eotaxin expression and eosinophil infiltrate in the liver of patients with drug-induced liver disease. , 2001, Journal of hepatology.

[27]  Albert P. Li,et al.  An integrated, multidisciplinary approach for drug safety assessment. , 2004, Drug discovery today.

[28]  Alexander Golbraikh,et al.  Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection , 2004, Molecular Diversity.

[29]  Mark T D Cronin,et al.  A review of the use of in silico methods to predict the chemistry of molecular initiating events related to drug toxicity , 2011, Expert opinion on drug metabolism & toxicology.

[30]  Ivan Rusyn,et al.  Predicting drug-induced hepatotoxicity using QSAR and toxicogenomics approaches. , 2011, Chemical research in toxicology.

[31]  Antony J. Williams,et al.  Free online resources enabling crowd-sourced drug discovery , 2009 .

[32]  Carol A Marchant,et al.  An Expert System Approach to the Assessment of Hepatotoxic Potential , 2009, Chemistry & biodiversity.

[33]  Ernesto Callegari,et al.  A comprehensive listing of bioactivation pathways of organic functional groups. , 2005, Current drug metabolism.

[34]  M. Madariaga,et al.  Drug-related hepatotoxicity. , 2006, The New England journal of medicine.

[35]  Sean Ekins,et al.  A Predictive Ligand-Based Bayesian Model for Human Drug-Induced Liver Injury , 2010, Drug Metabolism and Disposition.

[36]  R. Schwabe,et al.  Mechanisms of Liver Injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[37]  S. Kakar,et al.  Histological patterns in drug-induced liver disease , 2009, Journal of Clinical Pathology.

[38]  A. Maekawa,et al.  Category analysis of the substituted anilines studied in a 28-day repeat-dose toxicity test conducted on rats: Correlation between toxicity and chemical structure , 2008, SAR and QSAR in environmental research.

[39]  Neil Kaplowitz,et al.  Idiosyncratic drug hepatotoxicity , 2005, Nature Reviews Drug Discovery.

[40]  V. Navarro,et al.  Human drug hepatotoxicity: a contemporary clinical perspective. , 2009, Expert opinion on drug metabolism & toxicology.

[41]  L. Formigli,et al.  Aponecrosis: Morphological and biochemical exploration of a syncretic process of cell death sharing apoptosis and necrosis , 2000, Journal of cellular physiology.

[42]  K. Tolman,et al.  Defining patient risks from expanded preventive therapies. , 2000, The American journal of cardiology.

[43]  U. Boelsterli,et al.  Mitochondrial protection by the JNK inhibitor leflunomide rescues mice from acetaminophen‐induced liver injury , 2007, Hepatology.

[44]  R. Green,et al.  AGA technical review on the evaluation of liver chemistry tests. , 2002, Gastroenterology.

[45]  S. Krähenbühl,et al.  Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. , 2005, Hepatology.

[46]  Ivan Rusyn,et al.  Modeling liver-related adverse effects of drugs using knearest neighbor quantitative structure-activity relationship method. , 2010, Chemical research in toxicology.

[47]  A. Suzuki,et al.  Drug induced hepatotoxicity: data from the Serbian pharmacovigilance database , 2011, Pharmacoepidemiology and drug safety.

[48]  Ailan Cheng,et al.  In Silico Prediction of Hepatotoxicity , 2009 .

[49]  K. Nilsson,et al.  Predictive models of hepatotoxicity using gene expression data from primary rat hepatocytes , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[50]  G. Tarantino,et al.  Drug-induced liver injury: is it somehow foreseeable? , 2009, World journal of gastroenterology.

[51]  Ignazio Grattagliano,et al.  Current Concepts of Mechanisms in Drug-Induced Hepatotoxicity , 2009, Current medicinal chemistry.

[52]  Michael Balls.  Modern Alternative Approaches to the Problem of Drug-induced Liver Injury , 2011, Alternatives to laboratory animals : ATLA.

[53]  L. Fabris,et al.  The patient presenting with isolated hyperbilirubinemia. , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[54]  Romualdo Benigni,et al.  Structure alerts for carcinogenicity, and the Salmonella assay system: a novel insight through the chemical relational databases technology. , 2008, Mutation research.

[55]  P Smith,et al.  Concordance of the toxicity of pharmaceuticals in humans and in animals. , 2000, Regulatory toxicology and pharmacology : RTP.

[56]  L. Formigli,et al.  Apoptosis shifts to necrosis via intermediate types of cell death by a mechanism depending on c-myc and bcl-2 expression , 2004, Cell and Tissue Research.

[57]  S. Krähenbühl,et al.  Hepatocellular Toxicity and Pharmacological Effect of Amiodarone and Amiodarone Derivatives , 2006, Journal of Pharmacology and Experimental Therapeutics.

[58]  Albert P. Li,et al.  A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. , 2002, Chemico-biological interactions.

[59]  Philip N. Judson,et al.  Using Argumentation for Absolute Reasoning about the Potential Toxicity of Chemicals , 2003, J. Chem. Inf. Comput. Sci..

[60]  Dominic P. Williams,et al.  Idiosyncratic toxicity: the role of toxicophores and bioactivation. , 2003, Drug discovery today.

[61]  Leo Breiman,et al.  Classification and Regression Trees , 1984 .

[62]  William M. Lee,et al.  Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. , 2006, Gastroenterology.

[63]  S. Tannenbaum,et al.  In vitro methods to study chemically-induced hepatotoxicity: a literature review. , 2005, Current drug metabolism.

[64]  Munir Pirmohamed,et al.  Genetic factors in the predisposition to drug-induced hypersensitivity reactions , 2006, The AAPS Journal.

[65]  Wei-Yin Loh,et al.  Classification and regression trees , 2011, WIREs Data Mining Knowl. Discov..

[66]  David A. Brenner,et al.  Mechanisms of Liver Injury. I. TNF-α-induced liver injury: role of IKK, JNK, and ROS pathways , 2006 .

[67]  Nigel Greene,et al.  Developing structure-activity relationships for the prediction of hepatotoxicity. , 2010, Chemical research in toxicology.

[68]  Paul B Watkins,et al.  Biomarkers for the diagnosis and management of drug-induced liver injury. , 2009, Seminars in liver disease.

[69]  Naomi L Kruhlak,et al.  Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans. Part A: use of FDA post-market reports to create a database of hepatobiliary and urinary tract toxicities. , 2009, Regulatory toxicology and pharmacology : RTP.

[70]  Nigel Greene,et al.  Computer systems for the prediction of toxicity: an update. , 2002, Advanced drug delivery reviews.

[71]  Weida Tong,et al.  Biomarkers for drug-induced liver injury , 2010, Expert review of gastroenterology & hepatology.

[72]  William M. Lee.  Acute Liver Failure in the United States , 2003, Annals of Internal Medicine.

[73]  Peter V. Henstock,et al.  Cellular imaging predictions of clinical drug-induced liver injury. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[74]  B. Strom,et al.  Toward improved adverse event/suspected adverse drug reaction reporting , 2003, Pharmacoepidemiology and drug safety.

[75]  M. Molokhia,et al.  Genetic and molecular factors in drug-induced liver injury: a review. , 2007, Current drug safety.

[76]  N. Kaplowitz,et al.  Mechanisms of drug-induced liver injury. , 2013, Clinics in liver disease.

[77]  Steven L. Dixon,et al.  In silico models for the prediction of dose-dependent human hepatotoxicity , 2003, J. Comput. Aided Mol. Des..

[78]  B. Andrews,et al.  New Technologies and Screening Strategies for Hepatotoxicity: Use of In Vitro Models , 2005, Toxicologic pathology.

[79]  G. V. Kass,et al.  AUTOMATIC INTERACTION DETECTION , 1982 .

[80]  G. Zlokarnik,et al.  In silico prediction of drug safety: despite progress there is abundant room for improvement. , 2004, Drug discovery today. Technologies.

[81]  Judith C. Madden,et al.  Assessment of Methods To Define the Applicability Domain of Structural Alert Models , 2011, J. Chem. Inf. Model..

[82]  R. Andrade,et al.  Drug-induced hepatotoxicity , 2003, The New England journal of medicine.

[83]  W. Tong,et al.  Quantitative structure‐activity relationship methods: Perspectives on drug discovery and toxicology , 2003, Environmental toxicology and chemistry.

[84]  Katie Chan,et al.  Structure-activity relationships for halobenzene induced cytotoxicity in rat and human hepatoctyes , 2007 .

[85]  Munir Pirmohamed,et al.  The role of metabolic activation in drug-induced hepatotoxicity. , 2005, Annual review of pharmacology and toxicology.

[86]  J H Lewis,et al.  Drug-induced liver disease. , 2000, Clinics in liver disease.

[87]  S. Polley,et al.  Advantages of glutamate dehydrogenase as a blood biomarker of acute hepatic injury in rats , 2002, Laboratory animals.

[88]  R. Flavell,et al.  Critical role of c-jun (NH2) terminal kinase in paracetamol- induced acute liver failure , 2006, Gut.

[89]  Michael P Holt,et al.  Drug-induced liver injury. , 2010, Handbook of experimental pharmacology.

[90]  Mark T. D. Cronin,et al.  Chapter 2:In Silico Tools for Toxicity Prediction , 2011 .

[91]  T. W. Schultz.  Chapter 14:Adverse Outcome Pathways: A Way of Linking Chemical Structure to In Vivo Toxicological Hazards , 2010 .

[92]  Mph Dr. Syed Rizwanuddin Ahmad MD.  Adverse drug event monitoring at the food and drug administration , 2007, Journal of General Internal Medicine.

[93]  H. Zimmerman,et al.  Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver , 1978 .

[94]  J C Madden,et al.  Integrating (Q)SAR models, expert systems and read-across approaches for the prediction of developmental toxicity. , 2010, Reproductive toxicology.

[95]  H. Yamada,et al.  The Japanese toxicogenomics project: application of toxicogenomics. , 2010, Molecular nutrition & food research.

[96]  Alexander Golbraikh,et al.  Predictive QSAR modeling workflow, model applicability domains, and virtual screening. , 2007, Current pharmaceutical design.

[97]  Luis G Valerio,et al.  In silico toxicology for the pharmaceutical sciences. , 2009, Toxicology and applied pharmacology.

[98]  Daniel L Villeneuve,et al.  Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment , 2010, Environmental toxicology and chemistry.

[99]  Naomi L Kruhlak,et al.  Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part C: use of QSAR and an expert system for the estimation of the mechanism of action of drug-induced hepatobiliary and urinary tract toxicities. , 2009, Regulatory toxicology and pharmacology : RTP.

[100]  Naomi L Kruhlak,et al.  Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part B. Use of (Q)SAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities. , 2009, Regulatory toxicology and pharmacology : RTP.

[101]  Philip Judson,et al.  Using In Silico Tools in a Weight of Evidence Approach to Aid Toxicological Assessment , 2010, Molecular informatics.

[102]  N. Kaplowitz,et al.  Drug-Induced Liver Injury , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.